CG Oncology Reports Third Quarter 2026 Financial Results and Provides Business
CG Oncology Reports Third Quarter 2026 Financial Results and Provides Business Updates • PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk and high-grade Ta NMIBC anticipated November 2026
• BOND-003 Cohort P and CORE-008 Cohort CX 12-month data anticipated December 2026
• Well-positioned to deliver on key milestones with approximately $984.5 million of cash, cash equivalents and marketable securities sufficient to fund operations through 2029
-- CG Oncology, Inc. (NASDAQ: CGON) today reported financial results for the third quarter ended September 30, 2026, and provided business updates. “We are entering an eventful period for CG Oncology as we look forward to sharing PIVOT-006 topline data this month. As a reminder, PIVOT-006 is the first randomized registrational trial in intermediate-risk and high-grade Ta NMIBC. Additionally, we expect to have 12-month data from both CORE-008 Cohort CX and BOND-003 Cohort P in December, which further strengthens the growing body of evidence for cretostimogene across the NMIBC landscape and supports our goal to address the broadest number of patients. We remain confident in cretostimogene’s potential to become a backbone therapy for patients and to create long-term value for shareholders,” stated Arthur Kuan, Chairman, President & Chief Executive Officer at CG Oncology.
• Strengthened Executive Leadership Team with the addition of life-science executive Isabel Kalofonos as Chief Commercial Officer
In October, the Company appointed Isabel Kalofonos as Chief Commercial Officer. Ms. Kalofonos brings more than 20 years of experience driving successful launches including PALSONIFY TM (paltusotine) and ELAHERE® (mirvetuximab soravtansine) through strong commercial execution, helping bring innovative therapies to patients at scale across the biotechnology and pharmaceutical industries.
• PIVOT-006 (intermediate-risk and high-grade Ta ≤ 3cm NMIBC): Phase 3 topline data November 2026
• CORE-008 Cohort CX (BCG-exposed HR and BCG-unresponsive NMIBC) 12-month data December 2026
• BOND-003 Cohort P (BCG-unresponsive papillary only NMIBC) 12-month data December 2026
• Completion of BLA submission in initial indication of BCG-unresponsive NMIBC with CIS with or without papillary disease Q4 2026
: Cash, cash equivalents and marketable securities as of September 30, 2026 were $984.5 million, compared with $1.0 billion as of June 30, 2026. The Company anticipates its existing cash, cash equivalents and marketable securities as of this date will be sufficient to fund operations through 2029.
: R&D expenses were $39.2 million for the third quarter of 2026, as compared to $27.9 million for the prior year period. The increase was primarily due to an increase in clinical trial expenses, including CMC costs, and an increase in compensation costs due to increased headcount.
: G&A expenses were $23.0 million for the third quarter of 2026, as compared to $23.3 million for the prior year period. The decrease was primarily due to a decrease in professional and consultant fees, partially offset by an increase in personnel-related expenses, including compensation costs from increased headcount, and an increase in other general G&A expenses.
: Net loss was $56.9 million, or $(0.64) per share, for the third quarter of 2026, as compared to a net loss of $43.8 million, or $(0.57) per share, for the prior year period. 2
Cretostimogene is an investigational, intravesically delivered oncolytic immunotherapy that has been studied in a clinical development program, which includes more than 700 patients with Non-Muscle Invasive Bladder Cancer (NMIBC). This program includes two Phase 3 clinical trials: BOND-003 for BCG-unresponsive NMIBC and PIVOT-006 for intermediate-risk and high-grade Ta ≤ 3cm NMIBC. Cretostimogene has received FDA Fast Track and Breakthrough Therapy designations for BCG-unresponsive NMIBC. CG Oncology also has a multi-cohort trial, CORE-008, evaluating the safety and efficacy of cretostimogene in BCG-exposed HR and BCG- unresponsive NMIBC. Additionally, we have initiated an Expanded Access Program for cretostimogene in North America for patients who are unresponsive to BCG and meet certain program eligibility requirements. Cretostimogene is an investigational candidate, and its safety and efficacy have not been established by the FDA or any other health authority.
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit: www.cgoncology.com.
CG Oncology cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to, statements regarding our anticipated cash runway; our future results of operations and financial position; the timing, progress, conduct and completion of our ongoing and planned clinical trials and preclinical studies of cretostimogene; the timing, availability, announcement, presentation and results of clinical data, including topline data from PIVOT-006 and 12-month data from BOND-003 Cohort P and CORE-008 Cohort CX; anticipated milestones in our development pipeline; the timing, completion, acceptance, review and outcome of regulatory filings and submissions for cretostimogene, including the anticipated completion of our BLA submission for BCG-unresponsive NMIBC; the timing or likelihood of regulatory approvals and the scope of any approved indication or product label; the potential safety, efficacy, therapeutic benefits, clinical utility, commercial potential and market opportunity of cretostimogene for patients with BCG-unresponsive, BCG-exposed, intermediate-risk and high-grade Ta NMIBC; and the potential for cretostimogene to address a broad range of NMIBC patients or become a backbone therapy. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: topline, preliminary, interim or 12-month clinical-trial results may not be complete, may differ from final results, may not be confirmed upon full analysis of the data, and may not predict future or longer-term results; data from one trial, patient population, cohort or 3 time point may not be predictive of results from other trials, populations, cohorts or time points; potential delays in the commencement, enrollment, conduct or completion of clinical trials, including the BOND-003, PIVOT-006 and CORE-008 trials; potential delays in the completion, submission, acceptance or review of our BLA, and the possibility that the FDA may not approve cretostimogene on the anticipated timeline, for the anticipated indication or label, or at all; we may use our capital resources sooner than expected, and our existing capital resources may be insufficient to achieve our anticipated milestones or fund operations for the period anticipated; our cash-runway estimates are based on assumptions regarding our current operating plans, expenses and capital requirements that may prove to be incorrect or may change; our dependence on third parties in connection with manufacturing, shipping, clinical and preclinical testing activities; results from earlier clinical trials and preclinical studies may not be predictive of future results; unexpected adverse side effects or inadequate efficacy of cretostimogene may limit or prevent its development, regulatory approval or commercialization; we may be unable to successfully develop, obtain approval for, manufacture or commercialize cretostimogene; and other risks described in our filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our annual report on Form 10-K and other filings that we make with the SEC from time to time (which are available at http://www.sec.gov). You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Full text with the tables
Exhibit 99.1
CG Oncology Reports Third Quarter 2026 Financial Results and Provides Business
Updates
• PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an
adjuvant therapy in intermediate-risk and high-grade Ta NMIBC anticipated
November 2026
• BOND-003 Cohort P and CORE-008 Cohort CX 12-month data anticipated December
2026
• BLA completion for BCG-unresponsive NMIBC anticipated Q4 2026
• Well-positioned to deliver on key milestones with approximately $984.5 million
of cash, cash equivalents and marketable securities sufficient to fund
operations through 2029
DALLAS, Texas, November 6, 2026 (GLOBE NEWSWIRE)
-- CG Oncology, Inc. (NASDAQ: CGON) today reported financial results for the
third quarter ended September 30, 2026, and provided business updates.
“We are entering an eventful period for CG Oncology as we look forward to
sharing PIVOT-006 topline data this month. As a reminder, PIVOT-006 is the first
randomized registrational trial in intermediate-risk and high-grade Ta NMIBC.
Additionally, we expect to have 12-month data from both CORE-008 Cohort CX and
BOND-003 Cohort P in December, which further strengthens the growing body of
evidence for cretostimogene across the NMIBC landscape and supports our goal to
address the broadest number of patients. We remain confident in cretostimogene’s
potential to become a backbone therapy for patients and to create long-term
value for shareholders,” stated Arthur Kuan, Chairman, President & Chief
Executive Officer at CG Oncology.
Corporate Highlights
• Strengthened Executive Leadership Team with the addition of life-science
executive Isabel Kalofonos as Chief Commercial Officer
◦
In October, the Company appointed Isabel Kalofonos as Chief Commercial Officer.
Ms. Kalofonos brings more than 20 years of experience driving successful
launches including PALSONIFY TM (paltusotine) and ELAHERE® (mirvetuximab
soravtansine) through strong commercial execution, helping bring innovative
therapies to patients at scale across the biotechnology and pharmaceutical
industries.
Anticipated 2026 Milestones
• PIVOT-006 (intermediate-risk and high-grade Ta ≤ 3cm NMIBC): Phase 3 topline
data November 2026
• CORE-008 Cohort CX (BCG-exposed HR and BCG-unresponsive NMIBC) 12-month data
December 2026
• BOND-003 Cohort P (BCG-unresponsive papillary only NMIBC) 12-month data
December 2026
• Completion of BLA submission in initial indication of BCG-unresponsive NMIBC
with CIS with or without papillary disease Q4 2026
Third Quarter Financial Highlights
•
Cash Position
: Cash, cash equivalents and marketable securities as of September 30, 2026 were
$984.5 million, compared with $1.0 billion as of June 30, 2026. The Company
anticipates its existing cash, cash equivalents and marketable securities as of
this date will be sufficient to fund operations through 2029.
•
Research and Development (R&D) Expenses
: R&D expenses were $39.2 million for the third quarter of 2026, as compared to
$27.9 million for the prior year period. The increase was primarily due to an
increase in clinical trial expenses, including CMC costs, and an increase in
compensation costs due to increased headcount.
•
General and Administrative (G&A) Expenses
: G&A expenses were $23.0 million for the third quarter of 2026, as compared to
$23.3 million for the prior year period. The decrease was primarily due to a
decrease in professional and consultant fees, partially offset by an increase in
personnel-related expenses, including compensation costs from increased
headcount, and an increase in other general G&A expenses.
•
Net Loss
: Net loss was $56.9 million, or $(0.64) per share, for the third quarter of
2026, as compared to a net loss of $43.8 million, or $(0.57) per share, for the
prior year period.
2
About Cretostimogene Grenadenorepvec
Cretostimogene is an investigational, intravesically delivered oncolytic
immunotherapy that has been studied in a clinical development program, which
includes more than 700 patients with Non-Muscle Invasive Bladder Cancer (NMIBC).
This program includes two Phase 3 clinical trials: BOND-003 for BCG-unresponsive
NMIBC and PIVOT-006 for intermediate-risk and high-grade Ta ≤ 3cm NMIBC.
Cretostimogene has received FDA Fast Track and Breakthrough Therapy designations
for BCG-unresponsive NMIBC. CG Oncology also has a multi-cohort trial, CORE-008,
evaluating the safety and efficacy of cretostimogene in BCG-exposed HR and BCG-
unresponsive NMIBC. Additionally, we have initiated an Expanded Access Program
for cretostimogene in North America for patients who are unresponsive to BCG and
meet certain program eligibility requirements. Cretostimogene is an
investigational candidate, and its safety and efficacy have not been established
by the FDA or any other health authority.
About CG Oncology
CG Oncology is a late-stage clinical biopharmaceutical company focused on
developing and commercializing a potential backbone bladder-sparing therapeutic
for patients afflicted with bladder cancer. CG Oncology sees a world where
urologic cancer patients may benefit from our innovative immunotherapies to live
with dignity and have an enhanced quality of life. To learn more, please visit:
www.cgoncology.com.
Forward-Looking Statements
CG Oncology cautions you that statements contained in this press release
regarding matters that are not historical facts are forward-looking statements.
The forward-looking statements are based on our current beliefs and expectations
and include, but are not limited to, statements regarding our anticipated cash
runway; our future results of operations and financial position; the timing,
progress, conduct and completion of our ongoing and planned clinical trials and
preclinical studies of cretostimogene; the timing, availability, announcement,
presentation and results of clinical data, including topline data from PIVOT-006
and 12-month data from BOND-003 Cohort P and CORE-008 Cohort CX; anticipated
milestones in our development pipeline; the timing, completion, acceptance,
review and outcome of regulatory filings and submissions for cretostimogene,
including the anticipated completion of our BLA submission for BCG-unresponsive
NMIBC; the timing or likelihood of regulatory approvals and the scope of any
approved indication or product label; the potential safety, efficacy,
therapeutic benefits, clinical utility, commercial potential and market
opportunity of cretostimogene for patients with BCG-unresponsive, BCG-exposed,
intermediate-risk and high-grade Ta NMIBC; and the potential for cretostimogene
to address a broad range of NMIBC patients or become a backbone therapy. Actual
results may differ from those set forth in this press release due to the risks
and uncertainties inherent in our business, including, without limitation:
topline, preliminary, interim or 12-month clinical-trial results may not be
complete, may differ from final results, may not be confirmed upon full analysis
of the data, and may not predict future or longer-term results; data from one
trial, patient population, cohort or
3
time point may not be predictive of results from other trials, populations,
cohorts or time points; potential delays in the commencement, enrollment,
conduct or completion of clinical trials, including the BOND-003, PIVOT-006 and
CORE-008 trials; potential delays in the completion, submission, acceptance or
review of our BLA, and the possibility that the FDA may not approve
cretostimogene on the anticipated timeline, for the anticipated indication or
label, or at all; we may use our capital resources sooner than expected, and our
existing capital resources may be insufficient to achieve our anticipated
milestones or fund operations for the period anticipated; our cash-runway
estimates are based on assumptions regarding our current operating plans,
expenses and capital requirements that may prove to be incorrect or may change;
our dependence on third parties in connection with manufacturing, shipping,
clinical and preclinical testing activities; results from earlier clinical
trials and preclinical studies may not be predictive of future results;
unexpected adverse side effects or inadequate efficacy of cretostimogene may
limit or prevent its development, regulatory approval or commercialization; we
may be unable to successfully develop, obtain approval for, manufacture or
commercialize cretostimogene; and other risks described in our filings with the
Securities and Exchange Commission (SEC), including under the heading “Risk
Factors” in our annual report on Form 10-K and other filings that we make with
the SEC from time to time (which are available at http://www.sec.gov). You are
cautioned not to place undue reliance on these forward-looking statements, which
speak only as of the date hereof, and we undertake no obligation to update such
statements to reflect events that occur or circumstances that exist after the
date hereof. All forward-looking statements are qualified in their entirety by
this cautionary statement, which is made under the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995.
Contacts:
Media
Sarah Connors
Vice President, Communications and Patient Advocacy, CG Oncology
[email protected]
Investor Relations
Megan Knight
Vice President, Investor Relations, CG Oncology
[email protected]
4
CG ONCOLOGY, INC.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)
(unaudited)
Thr… Nine
Mon… Mon…
End… End…
Sep… Sep…
30, 30,
R… 2026 20… 2026 20…
──────────────────────────────────────────────────────────────────────────────
C…
a… $ 1,… $ 1,5… $ 3,… $ 1,5…
d…
r…
L…
a… — 158 24 210
c…
r…
T… 1,… 1,6… 3,… 1,7…
r…
O…
c…
a…
e…
C…
of 2,… 1,5… 9,… 1,5…
s…
R…
a… 39… 27,… 13… 86,…
d…
G…
a… 22… 23,… 72… 55,…
a…
T…
o…
c… 64… 52,… 21… 143…
a…
e…
L…
f… -6… -51… -2… -14…
o…
O…
i…
(…
n…
I…
i… 6,… 7,4… 20… 22,…
n…
O…
(… -65 -100 -1… -99
i…
n…
T…
o… 6,… 7,3… 19… 22,…
i…
n…
N…
l…
a… $ -5… $ -43… $ -1… $ -11…
c…
l…
N…
l…
p…
s… $ -0… $ -0.… $ -2… $ -1.…
b…
a…
d…
W…
a…
s…
of
c… 88,… 76… 87,… 76…
s…
o…
b…
a…
d…
CG ONCOLOGY, INC.
Consolidated Balance Sheet Data
(In thousands)
September 30, 2026 December 31, 2025
──────────────────────────────────────────────────────────────────────────────
-unaudited
Cash, cash
equivalents, and $ 984,458 $ 742,155
marketable
securities
Total assets 1,046,670 791,592
Total liabilities 55,704 38,990
Total
stockholders' 990,966 752,602
equity
5